2. Search Result
Search Result
Results for "

intrinsic clearance

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162238
    OSM-S-106

    		Parasite Infection
    OSM-S-106 is a pro-inhibitor and that inhibition of PfAsnRS occurs via enzyme-mediated production of an Asn-OSM-S-106 adduct. OSM-S-106 inhibits protein translation and activates the amino acid starvation response. OSM-S-106 exhibits selective activity against Plasmodium blood and liver stages and low intrinsic clearance by human microsomes .
    OSM-S-106
  • HY-146112
    IRAK4-IN-14

    		IRAK Cancer
    IRAK4-IN-14 (compound 28) is a potent, selective and orally active IRAK4 inhibitor with an IC50 of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .
    IRAK4-IN-14
  • HY-100432
    LOC14
    2 Publications Verification

    		 PDI Neurological Disease Inflammation/Immunology
    LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding . LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells .
    LOC14
  • HY-151096
    ACT-660602

    		CXCR Inflammation/Immunology
    ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC50 value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research .
    ACT-660602
  • HY-146113
    IRAK4-IN-15

    		IRAK Cancer
    IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC50 of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .
    IRAK4-IN-15
  • HY-146111
    IRAK4-IN-13

    		IRAK Cancer
    IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .
    IRAK4-IN-13
  • HY-148075
    PI4KIIIbeta-IN-11

    		PI4K Infection
    PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC50 value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum .
    PI4KIIIbeta-IN-11
  • HY-121814A
    (R)-Acenocoumarol

    (R)-Acenocoumarin; (R)-Nicoumalone

    		 Others Others
    (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a short-acting oral anticoagulant that, like warfarin, works by inhibiting vitamin K epoxide reductase. In vitro evaluations have shown that (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a higher intrinsic anticoagulant potency than warfarin and phenprocoumon. (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a single chiral center that produces two different enantiomeric forms. (R)-(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a longer plasma elimination half-life (6.6 hours) and a slower plasma clearance rate (1.9 L/hour) compared to the (S)-enantiomer (1.8 hours, 28.5 L/hour). (R)-(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a more potent anticoagulant in vivo than the (S)-enantiomer.
    (R)-Acenocoumarol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: